A detailed history of Peregrine Capital Management LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Peregrine Capital Management LLC holds 1,012,635 shares of CHRS stock, worth $1.06 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,012,635
Previous 1,016,455 0.38%
Holding current value
$1.06 Million
Previous $2.43 Million 27.91%
% of portfolio
0.05%
Previous 0.07%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$1.58 - $2.51 $6,035 - $9,588
-3,820 Reduced 0.38%
1,012,635 $1.75 Million
Q1 2024

Apr 26, 2024

SELL
$2.02 - $3.14 $148,482 - $230,808
-73,506 Reduced 6.74%
1,016,455 $2.43 Million
Q4 2023

Jan 26, 2024

SELL
$1.59 - $3.85 $458,883 - $1.11 Million
-288,606 Reduced 20.94%
1,089,961 $3.63 Million
Q3 2023

Oct 19, 2023

SELL
$3.74 - $5.45 $220,607 - $321,473
-58,986 Reduced 4.1%
1,378,567 $5.16 Million
Q2 2023

Jul 26, 2023

BUY
$3.79 - $8.3 $1.4 Million - $3.07 Million
370,369 Added 34.71%
1,437,553 $6.14 Million
Q1 2023

Apr 26, 2023

SELL
$5.89 - $10.52 $296,255 - $529,134
-50,298 Reduced 4.5%
1,067,184 $7.3 Million
Q4 2022

Jan 10, 2023

SELL
$5.69 - $10.07 $68,985 - $122,088
-12,124 Reduced 1.07%
1,117,482 $8.85 Million
Q3 2022

Oct 26, 2022

BUY
$7.17 - $13.87 $375,141 - $725,692
52,321 Added 4.86%
1,129,606 $10.9 Million
Q2 2022

Jul 20, 2022

BUY
$5.86 - $13.23 $763,124 - $1.72 Million
130,226 Added 13.75%
1,077,285 $7.8 Million
Q1 2022

Apr 27, 2022

BUY
$10.92 - $16.41 $2.25 Million - $3.38 Million
206,139 Added 27.82%
947,059 $12.2 Million
Q4 2021

Jan 31, 2022

SELL
$15.81 - $18.99 $2.16 Million - $2.59 Million
-136,365 Reduced 15.54%
740,920 $11.8 Million
Q3 2021

Nov 02, 2021

SELL
$12.68 - $17.79 $2.29 Million - $3.21 Million
-180,589 Reduced 17.07%
877,285 $14.1 Million
Q2 2021

Aug 03, 2021

BUY
$12.95 - $15.41 $2.42 Million - $2.88 Million
187,151 Added 21.49%
1,057,874 $14.6 Million
Q1 2021

May 11, 2021

SELL
$14.42 - $21.39 $447,942 - $664,458
-31,064 Reduced 3.44%
870,723 $12.7 Million
Q4 2020

Jan 19, 2021

BUY
$16.56 - $18.94 $6.24 Million - $7.14 Million
376,895 Added 71.8%
901,787 $15.7 Million
Q3 2020

Oct 20, 2020

BUY
$17.41 - $19.89 $1.39 Million - $1.58 Million
79,635 Added 17.89%
524,892 $9.63 Million
Q2 2020

Jul 30, 2020

BUY
$14.43 - $19.16 $91,861 - $121,972
6,366 Added 1.45%
445,257 $7.95 Million
Q1 2020

Apr 17, 2020

SELL
$11.67 - $22.53 $58,011 - $111,996
-4,971 Reduced 1.12%
438,891 $7.12 Million
Q4 2019

Jan 16, 2020

BUY
$16.33 - $21.37 $3.38 Million - $4.42 Million
206,771 Added 87.21%
443,862 $7.99 Million
Q3 2019

Oct 16, 2019

BUY
$16.3 - $23.37 $3.86 Million - $5.54 Million
237,091 New
237,091 $4.8 Million

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $81.6M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Peregrine Capital Management LLC Portfolio

Follow Peregrine Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peregrine Capital Management LLC with notifications on news.